Revive Therapeutics Announces Closing of Second Tranche of Private Placement
Revive Therapeutics (OTCQB: RVVTF), a specialty life sciences company, has completed the second tranche of its private placement by issuing 4,352,381 units at $0.021 per unit, raising gross proceeds of $91,400.
Each unit consists of one common share and one warrant, with warrants exercisable at $0.05 per share for 36 months. The proceeds will be used for working capital and trade payables settlement. Securities issued are subject to a four-month hold period ending January 19, 2026.
Revive Therapeutics (OTCQB: RVVTF), una società specializzata nelle scienze della vita, ha completato la seconda tranche della sua offerta privata emettendo 4.352.381 unità al prezzo di $0,021 per unità, raccogliendo proventi lordi per $91.400.
Ogni unità è composta da una azione ordinaria e un warrant (diritto di sottoscrizione), con i warrant che possono essere esercitati a $0,05 per azione per 36 mesi. I proventi saranno destinati a capitale circolante e al saldo delle passività commerciali. I titoli emessi sono soggetti a un periodo di blocco di quattro mesi che termina il 19 gennaio 2026.
Revive Therapeutics (OTCQB: RVVTF), una empresa especializada en ciencias de la vida, ha completado la segunda tramo de su colocación privada emitiendo 4,352,381 unidades a $0,021 por unidad, obteniendo ingresos brutos de $91.400.
Cada unidad consta de una acción ordinaria y un warrant (derecho de suscripción), con derechos de suscripción que pueden ejercerse a $0,05 por acción durante 36 meses. Los ingresos se destinarán a capital de trabajo y liquidación de cuentas por pagar comerciales. Los valores emitidos están sujetos a un periodo de bloqueo de cuatro meses que finaliza el 19 de enero de 2026.
Revive Therapeutics (OTCQB: RVVTF)는 전문 생명과학 기업으로, 비공개 배정의 두 번째 트랜치를 완료하고 단위당 $0.021에 4,352,381단위를 발행하여 총 인수금액 $91,400를 조달했습니다.
각 단위는 보통주 1주와 1개의 워런트로 구성되며, 워런트는 주당 $0.05에 36개월간 행사 가능합니다. 조달금은 운전자본 및 매입채무 상환에 사용되며 발행된 증권은 2026년 1월 19일 종료되는 4개월 간의 보유기간이 적용됩니다.
Revive Therapeutics (OTCQB: RVVTF), une société spécialisée dans les sciences de la vie, a terminé la deuxième tranche de son placement privé en émettant 4 352 381 unités à 0,021 $ l’unité, ce qui représente une somme brute de 91 400 $.
Chaque unité comprend une action ordinaire et un warrant (bon de souscription), les warrants pouvant être exercés à 0,05 $ par action pendant 36 mois. Les fonds provenant de l’opération seront destinés au fonds de roulement et au règlement des dettes commerciales. Les valeurs émises sont soumises à une période de blocage de quatre mois se terminant le 19 janvier 2026.
Revive Therapeutics (OTCQB: RVVTF), ein spezialisiertes Life-Sciences-Unternehmen, hat die zweite Tranche seiner privaten Platzierung abgeschlossen, indem 4.352.381 Einheiten zu 0,021 $ pro Einheit ausgegeben wurden, was Bruttoemissionen von 91.400 $ ergibt.
Jede Einheit besteht aus einer Stammaktie und einem Warrants, der Warrants können zu 0,05 $ pro Aktie für 36 Monate ausgeübt werden. Die Erlöse sollen für Betriebskapital und die Abwicklung von Handelsverbindlichkeiten verwendet werden. Die emittierten Wertpapiere unterliegen einer viermonatigen Haltedauer bis zum 19. Januar 2026.
Revive Therapeutics (OTCQB: RVVTF)، وهي شركة متخصصة في علوم الحياة، أكملت الجولة الثانية من عرضها الخاص بإصدار 4,352,381 وحدة بسعر 0.021 دولار للوحدة، محققة عوائد إجمالية قدرها 91,400 دولار.
كل وحدة تتكون من سهم عادي واحد ووتيرنت واحد، وتُمارس الوتيرنت بسعر 0.05 دولار للسهم لمدة 36 شهراً. ستُستخدم العائدات في رأس المال العامل وتسوية الذمم التجارية. الأسهم المصدرة خاضعة لفترة حظر مدتها أربعة أشهر تنتهي في 19 يناير 2026.
Revive Therapeutics (OTCQB: RVVTF)，是一家专注生命科学的公司，已完成私募的第二笔分期发行，发行了4,352,381份单位，单位价格为$0.021，毛收入总额为$91,400。
每份单位包含一股普通股和一个认股权证，认股权证可在每股$0.05、36个月内行使。募集资金将用于营运资金和应付账款的清偿。发行的证券受四个月锁定期约束，锁定期于2026年1月19日结束。
- Raised additional working capital of $91,400
- Warrants provide potential for additional future funding at $0.05 per share
- Significant dilution to existing shareholders at a low price of $0.021 per unit
- Low-priced offering indicates potential financial distress
- Funds primarily used for working capital and payables rather than growth initiatives
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of
Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at an exercise price of
The gross proceeds from the private placement offering will be used for working capital and payment of certain trade payables.
All of the securities issued are subject to a hold period of four months and one day expiring on January 19, 2026.
About Revive Therapeutics Ltd.
Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at www.sedarplus.ca.
FAQ
What is the size and price of Revive Therapeutics' (RVVTF) second tranche private placement?
What are the terms of the warrants in RVVTF's private placement?
How will Revive Therapeutics use the proceeds from this private placement?
When does the hold period expire for RVVTF's private placement securities?
What is the total potential dilution from RVVTF's private placement including warrants?
